Abstract library

568 results for "growth factor".
#2012 Expression and Clinical Significance of Vascular Endothelial Growth Factor D in Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: The expression of vascular endothelial growth factor D (VEGF-D) in tumor cells versus stroma cells in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and its clinical significance is still unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Y, Chen M, ...
#2011 Expression and Clinical Significance of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Phospho-VEGFR3 in Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: The expression of vascular endothelial growth factor Receptor 3 (VEGFR3) and phospho-VEGFR3 (pVEGFR3) in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and their clinical significance are still unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Y, Chen M, ...
#47 Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in Patients with Neuroendocrine Tumors
Introduction: Carcinoid heart disease (CHD) is a known complication of neuroendocrine tumors (NETs), particularly of those arising from the small intestine, appendix and proximal colon (previously known as mid-gut carcinoids). CHD is characterized by right heart fibrotic lesions and has traditionally been defined by the degree of valvular involvement, most commonly in the form of tricuspid regurgitation. Right ventricular (RV) dysfunction due to mural involvement may also be a manifestation. Connective tissue growth factor (CCN2) is upregulated in many fibrotic disorders. Increased tumor expression of CCN2 has been shown in patients with small intestinal NETs associated with peritoneal fibrosis. At present, its role in carcinoid heart disease is unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Deidi S Bergestuen
#304 Hepatic Neuroendocrine Tumor Metastasis Proliferation is Hepatocyte Regulated Via a 5HT7 Mediated Induction of an IGF 1 and HGF Feedback Loop Mediated by cAMP, PKA-independent pAKT and pCREB
Introduction: Carcinoid serotonin (5-HT) causes local fibrosis but the effect of 5-HT on hepatocytes has not been established. We hypothesized that tumors and hepatocytes form a metastasis-supportive environment.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
Authors: Svejda B, Kidd M, Lawrence B, Alaimo D, ...
#2269 Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?
Introduction: Altered expression of Insulin-like Growth Factor-1 (IGF-1), its receptor (IGF-1R), Connective Tissue Growth Factor (CTGF) and Hypoxia Factor-1 (HIF-1), has been implicated in tumorigenesis. These factors have not been studied systematically in Pulmonary Carcinoids (PCs).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: M.D, Ph.D. Apostolos Tsolakis
Keywords: IGF-1, IGF-1R, CTGF, HIF-1, Ki-67
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...
#911 Immunohistochemical Expression of Connective Tissue Growth Factor and Insulin-like Growth Factor-1 in Lung Carcinoids
Introduction: Several studies have shown altered expression of Insulin-like Growth Factor-1 (IGF-1) and its receptor (IGF-1R) in different types of cancers. Connective Tissue Growth Factor (CTGF) is triggered by Serotonin (5-HT) and Hypoxia Induced Factor 1 (HIF-1) and has been associated with tumor expansion and desmoplastic reaction in carcinoid tumors.
Conference: 11th Annual ENETS Conference (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: George A Kanakis
Keywords: lung, carcinoid, CTGF, IGF-1
#226 Insulin-like Growth Factor-1 Receptor (IGF-1R) and its Inhibition in Non-functioning Neuroendocrine Tumors
Introduction: Insulin-like growth factor-1 receptor (IGF-1R) was reported to be expressed in NET (neuroendocrine tumor) cells but its biological roles and activation status in non-functioning NET are unknown.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Sasano H, Iida S, Ono K, Nakamura Y, ...
#2008 Preliminary Evaluation of Influence of Different Targeted Drugs of Vascular Endothelial Growth Factor Signaling Pathway on the Proliferation of Neuroendocrine Neoplasm Cell Lines
Introduction: Sunitinib and bevacizumab are intracellular and extracellular inhibitor of vascular endothelial growth factor(VEGF) pathway respectively, the influence of both of which on the proliferation of neuroendocrine neoplasm (NEN) cell lines in vitro was not known yet.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Y, Chen M, ...
#219 Predictive Factors of Tumor Control in Patients with Well-differentiated Digestive Endocrine Carcinomas (WDEC) Treated with Lanreotide
Introduction: Somatostatin analogues (SSA) are indicated in the control of secretory symptoms of digestive endocrine tumors. The antiproliferative effect of SSA was recently demonstrated (Rinke et al, JCO 2009).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Philippe Ruszniewski
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team